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Abstract
An epidemic IMP-13 metallo-b-lactamase (MBL)-producing Pseu-
domonas aeruginosa clone, causing infections and even large
outbreaks in Italian critical care settings, was detected in a
young cystic ﬁbrosis patient. In this patient, the chronic infec-
tion was sustained by distinct clonal sub-populations of the
MBL-producing P. aeruginosa clone, either susceptible or resis-
tant to carbapenems. These ﬁndings underscore the impor-
tance of infection prevention practices in cystic ﬁbrosis
settings and pose an important diagnostic and therapeutic
challenge.
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Pseudomonas aeruginosa is a major pathogen for patients with
end-stage chronic obstructive pulmonary disease, including
patients with cystic ﬁbrosis (CF) [1], in whom it establishes a
persistent respiratory infection with recurrent exacerbations
[2].
P. aeruginosa is prone to acquire antibiotic resistance and
multidrug resistant (MDR) clones represent an important
therapeutic challenge [1]. In CF patients, infection by MDR
P. aeruginosa clones has been associated with a more severe
prognosis [3], and cross-contamination with similar clones is
a matter of major concern [4].
Acquired metallo-b-lactamases (MBLs) are emerging resis-
tance determinants of increasing clinical importance. MBLs
can confer a very broad spectrum of resistance to b-lactams
(including the expanded-spectrum cephalosporins and carba-
penems), which is not reversible by the available b-lactamase
inhibitors. Due to linkage of MBL genes with other resistance
genes, MBL-producing strains usually exhibit a complex MDR
phenotype [5]. MBL-producing P. aeruginosa have been
reported worldwide in nosocomial settings, sometimes caus-
ing major outbreaks [5]. However, their presence in CF
patients has not been reported, except for a single report in
Portugal [6].
In this paper we demonstrate the acquisition of an MBL-
producing epidemic P. aeruginosa clone in a CF patient; the
MBL-producing strain caused a chronic infection that was
sustained by distinct clonal sub-populations with a different
carbapenem resistance phenotype.
A female CF patient, monitored at a paediatric hospital in
Rome (Italy), was ﬁrst colonized by an MDR P. aeruginosa at
the age of 6 years and subsequently developed a chronic
infection. Before infection by P. aeruginosa, the patient had
received prophylaxis with aerosolized tobramycin and
azithromycin (since the ages of 6 months and 5 years,
respectively), and had occasionally received expanded-spec-
trum cephalosporins and ciproﬂoxacin. In the 6-year follow-
up period after P. aeruginosa infection, the patient presented
with several episodes of acute exacerbations (average 2 per
year), with a progressive decline of FEV1 (61% at the end of
the follow-up period), and received intermittent inhaled tob-
ramycin and azithromycin therapy; exacerbation episodes
were treated with ciproﬂoxacin, expanded-spectrum cepha-
losporins and, only in one case, with carbapenems.
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Eighteen isolates of P. aeruginosa, taken at different times
during the chronic infection, were available for microbiological
investigation. Cultures were derived from the original frozen
stocks. All isolates exhibited an MDR phenotype, including
ceftazidime, tobramycin and ciproﬂoxacin, while retained
susceptibility to piperacillin-tazobactam and colistin. Amikacin
susceptibility was variable, with MICs close to the breakpoint.
Carbapenem susceptibility was variable, with imipenem and
meropenem MICs either in the susceptible range (£4 mg/L) or
well above the resistance breakpoint (>32 mg/L). Carba-
penem-susceptible isolates were detected after the initial
isolation of a carbapenem-resistant isolate, and they coexisted
with carbapenem-resistant isolates over time (Table 1).
Pulsed-ﬁeld gel electrophoresis (PFGE) genotyping [7]
revealed a clonal relationship for all isolates; the infecting
clone was named OBG6.
The presence of major carbapenem resistance mecha-
nisms, namely carbapenemase production, reduced OprD
expression and upregulation of the MexAB-OprM efﬂux sys-
tem, was investigated. Spectrophotometric assay with crude
extracts [8] revealed production of EDTA-inhibitable carba-
penemase activity in all the OBG6 isolates, without signiﬁcant
differences in enzyme activity between the carbapenem-sus-
ceptible and carbapenem-resistant ones (Table 1). Multiplex
PCR for detection of blaIMP- and blaVIM-type MBL genes [8]
revealed the presence of a blaIMP allele, identiﬁed as blaIMP-13
by sequencing. MexAB-OprM efﬂux pump and OprD porin
expression levels were analysed by real-time (RT)-PCR; the
gyrB gene was used as housekeeping reference gene; ampliﬁ-
cation reactions were performed using the following primers:
oprD_Fwd 5¢-GAACTCTATGCCACCTACGC-3¢ and opr-
D_Rev 5¢-TGTTGAAATCGAAGCCCAGC-3¢, MexB2-Fwd
5¢-AACGGGATCGACAATCTGCG-3¢ and MexB2-Rev 5¢-
GAAGTTCTTCACCGCCTTGG-3¢, gyrB-PSA_Fwd 5¢-AA
GGTCTGGGAACAGGTCTA-3¢ and gyrB-PSA_Rev 5¢-AG
GATGTCCCAACTGAAGTG-3¢. Real-time (RT)-PCR reve-
aled a two- to nine-fold increased expression of the mexB
gene and a decreased (0.9–0.1-fold) oprD gene expression in
all isolates (Table 1), without any apparent relation to sus-
ceptibility to carbapenems. Sequencing of the oprD gene,
using primers designed on the gene ﬂanking sequences
(oprD-EXT-Fwd 5¢-CTATCGCCAAGAAACACTGC-3¢, oprD-
EXT-Rev 5¢-CTACGCCCTTCCTTTATAGG-3¢), revealed
the presence of an oprD-TS allele [9,10] in all isolates, and a
single nucleotide deletion (position +594) causing premature
translational termination of the protein (OprD-DTS) in carb-
apenem-resistant isolates (Table 1).
As an epidemic IMP-13-producing P. aeruginosa clone
has recently been reported, even as a cause of nosocomial
outbreaks [11,12], the OBG6_1 strain was compared with
representatives of the epidemic clone isolated in Italy. Analy-
sis of the PFGE proﬁles revealed clonal relatedness for all
isolates (Fig. 1), showing an identical PFGE proﬁle for
OBG6_1 and AV13X-28 strains and a difference of 1–3
bands between OBG6_1 and the other epidemic strains. By
multilocus sequence typing, the OBG6 clone belonged in
TABLE 1. Antimicrobial susceptibility and resistance mechanisms of the Pseudomonas aeruginosa isolates from a patient with
cystic ﬁbrosis
Isolate
Isolation
date
MIC mg/La
MBL Activityc
Gene expressiond
oprD-TS
alleleeCAZb TZP IMP MEM TOB AK CIP mexAB oprD-TS
OBG6_1 2004 Feb 12 >256 8 >32 >32 >64 32 >32 181 8.47 ± 0.89 0.32 ± 0.05 oprD-DTS
OBG6_2 2004 Sep 30 >256 8 4 1 >64 32 >32 186 6.93 ± 1.46 0.39 ± 0.08 wt
OBG6_3 2005 Jun 24 >256 4 >32 >32 >64 16 >32 190 NDf ND oprD-DTS
OBG6_4 2005 Oct 11 >256 8 4 1 >64 16 >32 192 ND ND wt
OBG6_5a 2006 Aug 30 >256 3 4 2 >64 24 >32 199 2.93 ± 0.71 0.13 ± 0.01 wt
OBG6_5b 2006 Aug 30 >256 2 >32 >32 >64 16 >32 189 3.88 ± 0.63 0.10 ± 0.05 oprD-DTS
OBG6_6a 2007 Jan 03 >256 2 4 1 >64 32 >32 131 5.93 ± 0.37 0.54 ± 0.02 wt
OBG6_6b 2007 Jan 03 >256 3 >32 >32 >64 16 >32 152 9.22 ± 0.61 0.26 ± 0.02 oprD-DTS
OBG6_7 2007 Feb 20 >256 8 >32 >32 >64 64 >32 130 ND ND oprD-DTS
OBG6_8a 2007 Sep 25 >256 16 >32 >32 >64 32 >32 133 6.94 ± 1.71 0.39 ± 0.01 oprD-DTS
OBG6_8b 2007 Sep 25 >256 8 >32 >32 >64 16 >32 207 9.26 ± 1.15 0.26 ± 0.03 oprD-DTS
OBG6_9 2008 Jun 08 >256 1.5 >32 >32 >64 12 >32 158 2.43 ± 0.16 0.35 ± 0.09 oprD-DTS
OBG6_10 2008 Dec 05 >256 2 >32 >32 >64 24 >32 142 ND ND oprD-DTS
OBG6_11 2009 Jun 03 >256 1 >32 >32 >64 16 >32 173 3.10 ± 0.25 0.33 ± 0.02 oprD-DTS
OBG6_12 2009 Oct 26 >256 1.5 4 1 >64 12 >32 199 4.64 ± 0.32 0.28 ± 0.05 wt
OBG6_13 2009 Nov 12 >256 1.5 >32 >32 >64 24 >32 133 4.25 ± 1.34 0.65 ± 0.17 oprD-DTS
OBG6_15a 2009 Nov 27 >256 1.5 3 1 >64 24 >32 204 8.60 ± 0.78 0.89 ± 0.09 wt
OBG6_15b 2009 Nov 27 >256 2 >32 >32 >64 24 >32 150 ND ND oprD-DTS
aAntibiotic susceptibility was determined using Etest (AB-Biodisk, Solna, Sweden) and interpreted according to the Clinical Laboratory Standards Institute [14].
bCAZ, ceftazidime; TZP, piperacillin-tazobactam; IMP, imipenem; MEM, meropenem; TOB, tobramycin; AK, amikacin; CIP, ciproﬂoxacin.
cEnzymatic activity of metallo-b-lactamase (MBL), obtained using imipenem as substrate (nMol/mg)1 min)1).
dGene expression fold-increase/decrease ± standard deviation, analysed using the ﬂuorescent dye SYBR Green I with the Lightcycler instrument (Roche-Applied Science, Mann-
heim, Germany); the P. aeruginosa susceptible wild-type strain PT5 was used as reference strain; the nalB mutant strain PT629, overexpressing MexAB-OprM, was used as
positive control strain [15].
eNucleotide sequence of the oprD allele; wt, wild-type oprD-TS allele; oprD-DTS, mutated allele.
fNot determined.
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ST621, which was already reported for IMP-13-producing
isolates disseminated worldwide, revealing a possibly com-
mon ancestor for these P. aeruginosa strains [12].
Moreover, analysis of the blaIMP-13 locus by PCR-mapping and
sequencing, revealed the presence in all OBG6 isolates of the
class 1 integron InPSG, harbouring the blaIMP-13 and aacA4 cas-
settes, which was previously described in an Italian study [11].
This study reports the isolation of an IMP-13-producing
P. aeruginosa clone, which was found to be epidemic in Italian
hospital settings, in a young CF patient; the strain was
involved in the ﬁrst colonization event of the patient and
persisted for a prolonged period. To the best of our knowl-
edge, this is the ﬁrst report of an IMP-type MBL-producing
P. aeruginosa strain in a CF setting.
Although patient-to-patient transmission of MBL-carrying
P. aeruginosa strains during chronic respiratory infections in
nosocomial settings has already been demonstrated [13],
information on transmission of such strains in CF settings is
poor. Our ﬁndings demonstrate the acquisition of a highly
transmissible nosocomial MBL-producing P. aeruginosa strain
in a CF patient and underline the importance of infection
prevention practices in the CF setting. Control practices
such as patient segregation, and the implementation of
appropriate hygienic measures and of disinfection procedures
have been recommended to prevent cross-infection and
appear to be of major importance in the case of MDR strain
transmission. Moreover, regular culturing of CF pathogens
and bacterial typing emerge as mandatory for epidemiological
surveillance. Furthermore, the role of chronically colonized
patients as a reservoir of such P. aeruginosa strains repre-
sents a matter of concern and could play a major role in
spreading of clinically relevant resistance determinants.
Our study demonstrates the chronic infection by distinct
clonal sub-populations of MBL-producing P. aeruginosa show-
ing different carbapenem resistance phenotypes; coexistence
for a long period of mutants of the OprD porin showing
high-level resistance to carbapenems with an apparently
susceptible wild-type strain was demonstrated. This ﬁnding
underlines the need for accurate diagnostic procedures, in
order to correctly detect chemoresistant bacterial sub-
populations; moreover, it could represent an important
therapeutic challenge, due to the possible selection of
resistant P. aeruginosa variants after repeated antibiotic
treatments.
Acknowledgements
We thank Thilo Ko¨hler for kindly providing P. aeruginosa
strains PT5 and PT629. These results were partially pre-
sented at the 49th Interscience Conference on Antimicrobial
Agents and Chemotherapy (ICAAC), San Francisco (USA),
September 2009.
Transparency Declaration
This work was partially supported by grants from the Italian
Cystic Fibrosis Research Foundation (Grants FFC#14/2006
and FFC#09/2008). The authors declare no conﬂicts of
interest.
References
1. Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis
and treatment of Pseudomonas aeruginosa infections. Drugs 2007; 67:
351–368.
FIG. 1. SpeI PFGE proﬁles of the IMP-13-producing Pseudomonas aeruginosa isolate OBG6_1 from a patient with cystic ﬁbrosis, strain AV65,
causing a nosocomial outbreak in southern Italy and representing the epidemic IMP-13 P. aeruginosa clone (clone C), and strains AV13X-28,
NA14X-12 and PG12X-03, representing the clonal variant C1, C2 and C3, respectively, present on the Italian territory [11,12]. Molecular size
standards are reported in kilobasepair.
1274 Clinical Microbiology and Infection, Volume 17 Number 8, August 2011 CMI
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1262–1282
2. Doring G, Hoiby N. Early intervention and prevention of lung
disease in cystic ﬁbrosis: a European consensus. J Cyst Fibros 2004; 3:
67–91.
3. Conway SP, Brownlee KG, Denton M, Peckham DG. Antibiotic treat-
ment of multidrug-resistant organisms in cystic ﬁbrosis. Am J Respir
Med 2003; 2: 321–332.
4. Saiman L, Siegel J. Infection control in cystic ﬁbrosis. Clin Microbiol
Rev 2004; 17: 57–71.
5. Queenan AM, Bush K. Carbapenemases: the versatile b-lactamases.
Clin Microbiol Rev 2007; 20: 440–458.
6. Cardoso O, Alves AF, Leitao R. Metallo-b-lactamase VIM-2 in Pseudo-
monas aeruginosa isolates from a cystic ﬁbrosis patient. Int J Antimicrob
Agents 2008; 31: 375–379.
7. Giske CG, Libisch B, Colinon C et al. Establishing clonal relationships
between VIM-1-like metallo-b-lactamase-producing Pseudomonas aeru-
ginosa strains from four European countries by multilocus sequence
typing. J Clin Microbiol 2006; 44: 4309–4315.
8. Docquier JD, Riccio ML, Mugnaioli C et al. IMP-12, a new plasmid-
encoded metallo-b-lactamase from a Pseudomonas putida clinical iso-
late. Antimicrob Agents Chemother 2003; 47: 1522–1528.
9. Edalucci E, Spinelli R, Dolzani L et al. Acquisition of different carbape-
nem resistance mechanisms by an epidemic clonal lineage of Pseudo-
monas aeruginosa. Clin Microbiol Infect 2008; 14: 88–90.
10. Epp SF, Kohler T, Plesiat P, Michea-Hamzehpour M, Frey J, Pechere
JC. C-terminal region of Pseudomonas aeruginosa outer membrane po-
rin OprD modulates susceptibility to meropenem. Antimicrob Agents
Chemother 2001; 45: 1780–1787.
11. Rossolini GM, Luzzaro F, Migliavacca R et al. First countrywide survey
of acquired metallo-b-lactamases in Gram-negative pathogens in Italy.
Antimicrob Agents Chemother 2008; 52: 4023–4029.
12. Santella G, Pollini S, Docquier JD et al. Intercontinental dissemination
of IMP-13-producing Pseudomonas aeruginosa belonging in sequence
Type 621. J Clin Microbiol 2010; 48: 4342–4343.
13. Juan C, Gutierrez O, Renom F et al. Chronic respiratory infections
by mucoid carbapenemase-producing Pseudomonas aeruginosa strains,
a new potential public health problem. Antimicrob Agents Chemother
2008; 52: 2285–2286.
14. Clinical and Laboratory Standards Institute. Performance standards for
antimicrobial susceptibility testing; 19th informational supplement. Wayne,
Pa: Clinical Laboratory Standards Institute, 2010.
15. Dumas JL, van DC, Perron K, Kohler T. Analysis of antibiotic resis-
tance gene expression in Pseudomonas aeruginosa by quantitative real-
time-PCR. FEMS Microbiol Lett 2006; 254: 217–225.
Understanding the dynamics of imipenem-
resistant Acinetobacter baumannii lineages
within Portugal
F. Grosso1, S. Quinteira1,2 and L. Peixe1
1) REQUIMTE, Laborato´rio de Microbiologia, Faculdade de Farma´cia,
Universidade do Porto, Porto and 2) Centro de Investigac¸a˜o em
Tecnologias da Sau´de (CITS)/IPSN (CESPU), VN Famalica˜o, Portugal
Abstract
A recent collection of 213 imipenem-resistant Acinetobacter bau-
mannii (IRAB) clinical isolates was characterized for the presence
of acquired carbapenem-hydrolysing class D b-lactamases
(CHDLs) and clonality. A population structure analysis of IRAB
was also conducted, with ﬁve molecular typing methods. Three
main clusters, each one associated with a speciﬁc CHDL, were
observed with multilocus sequence typing. Overall, our results sug-
gest a switch in the dominant clone, with sequence type (ST) 92,
carrying blaOXA-23 (63.4%), replacing the closely related ST98,
carrying blaOXA-24/40 (22%). In addition, ST103, an independent
lineage, was associated with blaOXA-58-carrying isolates (14.6%).
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During the last decade, an ongoing rise in Acinetobacter
baumannii carbapenem resistance has been observed
worldwide, with recent reports of resistance to all available an-
timicrobials [1,2]. The production of acquired carbapenem-hy-
drolysing class D b-lactamases (CHDLs) belonging to the
OXA-23, OXA-24/40 and OXA-58 groups is the main
reported carbapenem resistance mechanism [1–7]. Despite the
description of two particular isolates producing IMP-5 [8] and,
more recently, OXA-23 [2], the imipenem resistance observed
in Portuguese A. baumannii clinical isolates has been mainly
associated with the production of OXA-24/40 and linked to
the spread of a particular multidrug-resistant clone [3,6].
Several sequence-based typing methods have been proposed
for A. baumannii population structure analyses [9–12], with
multilocus sequence typing (MLST) being increasingly applied as
a standard method [4,5,10,11,13]. Nevertheless, studies evalu-
ating the robustness of each particular method are still scarce.
In this work, we have characterized the antimicrobial sus-
ceptibility, acquired CHDLs and clonality of 213 previously
undescribed imipenem-resistant A. baumannii (IRAB) isolates,
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